Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.02 -18.4%	$3.08	$2.01 ▼ $5.64	$200.91M	1.61	1.19 million shs	3.72 million shs
DBVT DBV Technologies	$9.85 +4.0%	$9.10	$2.20 ▼ $12.78	$269.79M	-0.63	190,309 shs	34,150 shs
SPK SPK Acquisition	$10.30	$10.22	$9.84 ▼ $10.68	$67.94M	-0.01	12,839 shs	33,515 shs
TVGN Semper Paratus Acquisition	$1.20 -1.6%	$1.15	$0.26 ▼ $3.09	$220.67M	-0.69	5.05 million shs	371,487 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-18.38%	-21.96%	+3.78%	-19.68%	+20.80%
DBVT DBV Technologies	+4.01%	+12.96%	-8.80%	+86.55%	+98.99%
SPK SPK Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
TVGN Semper Paratus Acquisition	-1.64%	-10.45%	+4.35%	+2.56%	+50.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.4707 of 5 stars	3.5	0.0	0.0	0.0	2.9	0.0	0.6
DBVT DBV Technologies	3.3751 of 5 stars	3.3	5.0	0.0	0.0	3.0	2.5	0.6
SPK SPK Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	3.9815 of 5 stars	3.5	4.0	0.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	3.00	Buy	$12.00	297.35% Upside
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	49.75% Upside
SPK SPK Acquisition	0.00	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	3.00	Buy	$7.10	491.67% Upside

Current Analyst Ratings Breakdown

Latest SPK, TVGN, CRDF, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/12/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	295.47	N/A	N/A	$1.86 per share	1.62
DBVT DBV Technologies	$4.15M	65.01	N/A	N/A	$1.42 per share	6.94
SPK SPK Acquisition	N/A	N/A	N/A	N/A	($0.19) per share	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
SPK SPK Acquisition	-$420K	N/A	0.00	∞	N/A	N/A	N/A	-1.95%	N/A
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)

Latest SPK, TVGN, CRDF, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
SPK SPK Acquisition	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
DBVT DBV Technologies	N/A	0.72	0.72
SPK SPK Acquisition	N/A	4.64	4.64
TVGN Semper Paratus Acquisition	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
DBVT DBV Technologies	71.74%
SPK SPK Acquisition	19.64%
TVGN Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
DBVT DBV Technologies	1.44%
SPK SPK Acquisition	22.40%
TVGN Semper Paratus Acquisition	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
SPK SPK Acquisition	2,021	6.60 million	5.12 million	Not Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A

SPK, TVGN, CRDF, and DBVT Headlines

Recent News About These Companies

Semper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

June 18 at 9:36 AM | marketbeat.com

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

June 18 at 8:30 AM | globenewswire.com

Tevogen Bio

June 17 at 11:45 AM | thepharmaletter.com

Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives

June 12, 2025 | nasdaq.com

Tevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral Capital

June 11, 2025 | americanbankingnews.com

Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft

June 10, 2025 | nasdaq.com

Tevogen Bio doubles Warren HQ footprint for AI expansion

June 10, 2025 | njbiz.com

Ambitious Tevogen makes expansion announcement

June 10, 2025 | thepharmaletter.com

Tevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral Capital

June 10, 2025 | marketbeat.com

Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

June 10, 2025 | insidertrades.com

Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of Stock

June 9, 2025 | marketbeat.com

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

June 9, 2025 | globenewswire.com

tevogen bio expands office lease in new jersey with key amendment

June 5, 2025 | investing.com

Tevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijziging

June 4, 2025 | nl.investing.com

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1, 2025 | nl.investing.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short Interest

June 1, 2025 | marketbeat.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30, 2025 | quiverquant.com

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral Capital

May 28, 2025 | marketbeat.com

Tevogen Peports Plans to Increase the Target Population for TVGN 489

May 26, 2025 | msn.com

Tevogen expands target for COVID treatment to seniors

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPK, TVGN, CRDF, and DBVT Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.02 -0.68 (-18.38%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.05 +0.03 (+0.99%)

As of 06/18/2025 07:55 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DBV Technologies NASDAQ:DBVT

$9.85 +0.38 (+4.01%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.77 -0.08 (-0.77%)

As of 06/18/2025 07:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

SPK Acquisition NASDAQ:SPK

SPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China.

Semper Paratus Acquisition NASDAQ:TVGN

$1.20 -0.02 (-1.64%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.08%)

As of 06/18/2025 06:44 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time